Cargando…
Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex
Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of IL-13 with IL-13Rα1 and subsequent signaling....
Autores principales: | Tollenaere, Maxim A.X., Mølck, Christina, Henderson, Ian, Pollack, Scott, Addis, Philip, Petersen, Helle Heibroch, Norsgaard, Hanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405097/ https://www.ncbi.nlm.nih.gov/pubmed/37554517 http://dx.doi.org/10.1016/j.xjidi.2023.100214 |
Ejemplares similares
-
IL-13Rα2 Glycosylation Holds the Dance Card for Partnering with
IL-13
por: Dy, Alane B. C., et al.
Publicado: (2020) -
Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity
por: Junttila, Ilkka S., et al.
Publicado: (2008) -
IL4Rα and IL13Rα1 Are Involved in the Development of Human Gallbladder Cancer
por: Ahn, Sung Woo, et al.
Publicado: (2022) -
Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes
por: Ulzii, Dugarmaa, et al.
Publicado: (2019) -
The IL-13/IL-4Rα axis is involved in tuberculosis-associated pathology
por: Heitmann, Lisa, et al.
Publicado: (2014)